Vanda Pharmaceuticals (VNDA) Intangibles (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly Intangibles of $115.1 million in Q1 2026, down 1.7% quarter-over-quarter from $117.1 million in Q4 2025, and up 2.45% year-over-year from $112.3 million in Q1 2025.
Vanda Pharmaceuticals' Intangibles history runs 17 years deep, the most recent figure standing at $115.1 million for Q1 2026.
- In Q1 2026, Intangibles rose 2.45% year-over-year to $115.1 million; the TTM figure through Mar 2026 stood at $115.1 million (up 2.45% YoY), while the FY2025 annual figure was $117.1 million, up 2.62% from the prior year.
- Intangibles came in at $115.1 million for Q1 2026 at Vanda Pharmaceuticals, down from $117.1 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $121.4 million in Q4 2023 to a low of $17.4 million in Q3 2023.
- A 5-year average of $75.4 million and a median of $110.6 million in 2025 frame the typical range for Intangibles.
- Across the five-year window, Intangibles declined 8.0% in 2023 and soared 564.72% in 2024, its largest moves.
- Vanda Pharmaceuticals' Intangibles stood at $18.6 million in 2022, then jumped by 553.75% to $121.4 million in 2023, then fell by 5.99% to $114.1 million in 2024, then gained by 2.62% to $117.1 million in 2025, then dropped by 1.7% to $115.1 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $115.1 million, $117.1 million, and $108.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.41 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 11,640.44 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 418.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.29 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | 115.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 115.10 Mn |
| Dec 31, 2025 | 117.09 Mn |
| Sep 30, 2025 | 108.84 Mn |
| Jun 30, 2025 | 110.59 Mn |
| Mar 31, 2025 | 112.34 Mn |
| Dec 31, 2024 | 114.10 Mn |
| Sep 30, 2024 | 115.85 Mn |
| Jun 30, 2024 | 117.60 Mn |
| Mar 31, 2024 | 119.35 Mn |
| Dec 31, 2023 | 121.37 Mn |
| Sep 30, 2023 | 17.43 Mn |
| Jun 30, 2023 | 17.81 Mn |
| Mar 31, 2023 | 18.19 Mn |
| Dec 31, 2022 | 18.57 Mn |
| Sep 30, 2022 | 18.94 Mn |
| Jun 30, 2022 | 19.32 Mn |
| Mar 31, 2022 | 19.70 Mn |
| Dec 31, 2021 | 20.08 Mn |
| Sep 30, 2021 | 20.45 Mn |
| Jun 30, 2021 | 20.82 Mn |
| Mar 31, 2021 | 21.19 Mn |
| Dec 31, 2020 | 21.56 Mn |
| Sep 30, 2020 | 21.93 Mn |
| Jun 30, 2020 | 22.30 Mn |
| Mar 31, 2020 | 22.67 Mn |
| Dec 31, 2019 | 23.04 Mn |
| Sep 30, 2019 | 23.41 Mn |
| Jun 30, 2019 | 23.78 Mn |
| Mar 31, 2019 | 24.16 Mn |
| Dec 31, 2018 | 24.54 Mn |
| Sep 30, 2018 | 24.92 Mn |
| Jun 30, 2018 | 25.32 Mn |
| Mar 31, 2018 | 25.72 Mn |
| Dec 31, 2017 | 26.07 Mn |
| Sep 30, 2017 | 26.50 Mn |
| Jun 30, 2017 | 26.93 Mn |
| Mar 31, 2017 | 27.37 Mn |
| Dec 31, 2016 | 60.94 Mn |
| Sep 30, 2016 | 29.92 Mn |
| Jun 30, 2016 | 60.94 Mn |
| Mar 31, 2016 | 35.81 Mn |
| Dec 31, 2015 | 60.94 Mn |
| Sep 30, 2015 | 41.70 Mn |
| Jun 30, 2015 | 60.94 Mn |
| Mar 31, 2015 | 25.00 Mn |
| Dec 31, 2014 | 15.90 Mn |
| Sep 30, 2014 | 11.32 Mn |
| Jun 30, 2014 | 11.86 Mn |
| Mar 31, 2014 | 12.47 Mn |
| Dec 31, 2013 | 5.04 Mn |
| Sep 30, 2013 | 5.41 Mn |
| Jun 30, 2013 | 12.00 Mn |
| Mar 31, 2013 | 12.00 Mn |
| Dec 31, 2012 | 6.53 Mn |
| Sep 30, 2012 | 6.91 Mn |
| Jun 30, 2012 | 7.29 Mn |
| Mar 31, 2012 | 7.66 Mn |
| Dec 31, 2011 | 12.00 Mn |
| Sep 30, 2011 | 8.40 Mn |
| Jun 30, 2011 | 8.78 Mn |
| Dec 31, 2010 | 9.52 Mn |